In This Section

Evolution of Drug Resistance

Tuesday April 05, 2022

8:00 am - 9:30 am Central Time (CT)

113 A


Chair :

Robert Gatenby
Moffitt Cancer Center

This session will explore how cancers evolve resistance to therapies. It will explore the importance of tumor heterogeneity, both genetic and epigenetic, and the microenvironment in the evolution of drug resistance. Attendees will also learn about the tradeoffs associated with drug resistance, and how these costs can be exploited for the design of more effective and less toxic therapeutic regimen. The application of evolutionary approaches to understand and to treat cancers will be demonstrated for multiple malignancies, including breast and prostate cancers and multiple myeloma.


Robert Gatenby - Moffitt Cancer Center

Exploiting Darwinian Dynamics to Delay or Prevent Evolution of Resistance in Treated Cancer Populations

Advances in drug development have produced many new effective cancer therapies but evolution of resistance remains a fundamental barrier to cure or prolonged control. Recent investigations of the Darwinian dynamics that govern proliferation of resistant cancer populations suggests evolution-based strategies may improve cancer treatment outcomes.

Ariosto Silva - Moffitt Cancer Center

Evolutionary Dynamics of Disease Progression and Therapy Resistance in Multiple Myeloma

The molecular mechanisms leading to disease progression and refractory disease in Multiple Myeloma (MM) remain poorly understood. Here we demonstrate preliminary data from a new cohort of MM patients, suggesting that multiple independent combinations of genetic and epigenetic events alter genome-wide transcriptional reprogramming, facilitating disease progression and emergence of therapy resistance.

Rena Emond - City of Hope

Combating Evolutionary Drug Resistance by Targeting Heterogenous Cell-cell Interactions

Tumor heterogeneity creates obstacles for treating cancer, such as a difference in susceptibilities to treatment, natural selection for drug resistance, and the possibility for interactions among cells to alter treatment response. With the use of an ER+ breast cancer in vitro system, we are able to investigate ecological interactions between cells sensitive and resistant to selective drug pressure in heterogenous cancer populations to probe for differences in growth, resistance, and cooperative communication between cell types. In doing so, we can better understand the consequences of these interactions and how they drive the evolution of therapy resistance in order to identify targets for long-term treatment strategies and combat refractory tumors.

Last Updated: March 27, 2022
Key Dates

Thank you to our Annual Meeting partners: